Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner

Christine Burkard1, Monique H. Verheije1, Oliver Wicht1, Sander I. van Kasteren2, Frank J. van Kuppeveld1, Bart L. Haagmans3, Lucas Pelkmans4, Peter J. M. Rottier1, Berend Jan Bosch1, Cornelis A. M. de Haan1

1 Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands, 2 Division of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands, 3 Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands, 4 Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland

Abstract

Enveloped viruses need to fuse with a host cell membrane in order to deliver their genome into the host cell. While some viruses fuse with the plasma membrane, many viruses are endocytosed prior to fusion. Specific cues in the endosomal microenvironment induce conformational changes in the viral fusion proteins leading to viral and host membrane fusion. In the present study we investigated the entry of coronaviruses (CoVs). Using siRNA gene silencing, we found that proteins known to be important for late endosomal maturation and endosome-lysosome fusion profoundly promote infection of cells with mouse hepatitis coronavirus (MHV). Using recombinant MHVs expressing reporter genes as well as a novel, replication-independent fusion assay we confirmed the importance of clathrin-mediated endocytosis and demonstrated that trafficking of MHV to lysosomes is required for fusion and productive entry to occur. Nevertheless, MHV was shown to be less sensitive to perturbation of endosomal pH than vesicular stomatitis virus and influenza A virus, which fuse in early and late endosomes, respectively. Our results indicate that entry of MHV depends on proteolytic processing of its fusion protein S by lysosomal proteases. Fusion of MHV was severely inhibited by a pan-lysosomal protease inhibitor, while trafficking of MHV to lysosomes and processing by lysosomal proteases was no longer required when a furin cleavage site was introduced in the S protein immediately upstream of the fusion peptide. Also entry of feline CoV was shown to depend on trafficking to lysosomes and processing by lysosomal proteases. In contrast, MERS-CoV, which contains a minimal furin cleavage site just upstream of the fusion peptide, was negatively affected by inhibition of furin, but not of lysosomal proteases. We conclude that a proteolytic cleavage site in the CoV S protein directly upstream of the fusion peptide is an essential determinant of the intracellular site of fusion.

Introduction

To achieve successful infection enveloped viruses need to fuse with a host cell membrane to deliver their genome into the host cell. Some viruses, such as herpes simplex virus, Sendai virus, and human immunodeficiency virus, appear to be capable of direct fusion at the plasma membrane after initial attachment [1–5]. However, the majority of enveloped viruses use endocytosis for uptake and transport prior to fusion. Since endocytic cargo may eventually end up in the destructive environment of the lysosome, environmental cues are crucial to trigger viral fusion at the right stage of trafficking. These triggers, which may include a decrease in pH, changes in redox environment, and proteolytic activity [6–8], induce conformational changes in the viral fusion proteins leading to the merger of viral and host membranes. Two well-studied viruses; influenza A virus (IAV) and vesicular stomatitis virus (VSV), are known to undergo fusion upon exposure to low pH [9–12]. Other enveloped viruses, such as respiratory syncytial virus (RSV) and Ebola virus, require proteolytic processing of their viral fusion proteins in the endosomal system for fusion to occur [13–16].

Coronaviruses (CoVs) are enveloped, plus-strand RNA viruses belonging to the family Coronaviridae in the order Nidovirales. They are capable of infecting a wide variety of mammalian and avian species. In most cases they cause respiratory and/or intestinal tract disease. Human coronaviruses (HCoVs) are known as major causes of the common cold (e.g. HCoV-229E and HCoV-OC43). However, the emergence of new HCoVs of zoonotic origin has shown the potential of CoVs to cause life-threatening disease in humans as was demonstrated during the 2002/2003 SARS-CoV epidemics and more recently for MERS-CoV in the Middle East [17,18]. The well-studied mouse hepatitis virus (MHV) is often used as a safe model to study CoV infections.
Author Summary

Enveloped viruses need to fuse with a host cell membrane in order to deliver their genome into the host cell. In the present study we investigated the entry of coronaviruses (CoVs). CoVs are important pathogens of animals and man with high zoonotic potential as demonstrated by the emergence of SARS- and MERS-CoVs. Previous studies resulted in apparently conflicting results with respect to CoV cell entry, particularly regarding the fusion-activating requirements of the CoV S protein. By combining cell-biological, infection, and fusion assays we demonstrated that murine hepatitis virus (MHV), a prototypic member of the CoV family, enters cells via clathrin-mediated endocytosis. Moreover, although MHV does not depend on a low pH for fusion, the virus was shown to rely on trafficking to lysosomes for proteolytic cleavage of its spike (S) protein and membrane fusion to occur. Based on these results we predicted and subsequently demonstrated that MERS- and feline CoV require cleavage by different proteases and escape the endo/lysosomal system from different compartments. In conclusion, we elucidated the MHV entry pathway in detail and demonstrate that a proteolytic cleavage site in the S protein of different CoVs is an essential determinant of the intracellular site of fusion.

All CoV virions contain a canonical set of four structural proteins. The viral genomic RNA is encapsulated by the nucleocapsid protein (N) to form the helical nucleocapsid, which is surrounded by the lipoprotein envelope, containing membrane glycoprotein (M), the small envelope protein (E), as well as the spike glycoprotein (S) [reviewed in (19)]. Trimmers of the CoV S protein, a type I membrane protein belonging to the class I fusion proteins, form the peplomers that protrude from the virion surface [20]. The S protein can be divided into two functional subunits. The amino-terminal S1 subunit contains the receptor-binding domain; while the carboxy-terminal S2 subunit contains domains required for fusion, including the fusion peptide (FP), heptad repeat domains (HR) HR1 and HR2, and the transmembrane (TM) domain.

Various entry routes have been described as being used by different CoVs for infection of cells. Clathrin-dependent as well as clathrin- and caveola-independent entry pathways have been reported for SARS-CoV [21,22]. Also feline infectious peritonitis virus (FIPV) was suggested to enter via a clathrin- and caveola-independent endocytic route [23,24]. For the HCoV-229E a caveola-dependent endocytic uptake has been suggested [25]. Although the ability of MHV S proteins to cause cell-cell fusion at a neutral pH was initially interpreted as an indication for fusion of virions at the cell surface, more recent studies indicate the requirement for clathrin-mediated endocytosis for entry of MHV [26–29]. However, while some studies report that MHV strain A59 is sensitive to lysosomotropic agents that affect endocytosis [26], this is not the case according to others [27].

Proteolytic cleavage of the CoV S proteins appears to be important for the induction of cell-cell fusion and/or virus entry into host cells. Different cleavage sites have been identified for different CoVs, the importance of which seems to differ for cell-cell and virus-cell fusion. Some CoV S proteins, including that of MHV strain A59, are cleaved at the S1/S2 boundary by furin-like proteases during transport of the newly assembled virions through the secretory pathway of the producer cell [30–33]. Inhibition of this S protein cleavage was shown to inhibit cell-cell fusion, but not to affect entry of MHV strain A59 into host cells [30,34,35]. MHV strain 2 contains an S protein that is not cleaved at the S1/S2 boundary. Interestingly, although MHV strains 2 and A59 were both reported to enter via clathrin-mediated endocytosis, entry of MHV 2 but not of MHV A59, was blocked by inhibitors of low-pH activated cathepsin proteases [27,36]. Inhibitors of cathepsin proteases have also been shown to inhibit entry of SARS-CoV and feline CoVs [23,37,30], while treatment of cell-bound virus particles with different proteases was shown to enhance virus entry and/or cell-cell fusion [27,34,39–45]. For SARS-CoV and infectious bronchitis virus (IBV), it appears that a proteolytic cleavage of the S protein at a more downstream position than the S1/S2 boundary upon receptor binding is of importance for cell entry [40,43,46–49].

In the present study we performed a detailed investigation of the entry of different CoVs. Using siRNA gene silencing, we found that the prototypic coronavirus MHV strain A59 (further referred to as MHV) requires proteins known to be important for late endosomal maturation and endosome-lysosome fusion for efficient infection of cells. By using recombinant MHVs expressing reporter genes as well as by applying a novel, replication-independent fusion assay we confirmed the importance of clathrin-mediated endocytosis and demonstrated that trafficking of MHV virions to lysosomal compartments and processing of the S protein by lysosomal proteases was required for productive entry to occur. Our results indicate that a cleavage site in the S protein of CoVs immediately upstream of the FP determines the site of fusion. In agreement herewith FIPV, which requires processing by lysosomal proteases, was also shown to depend on trafficking to lysosomes. In contrast, MERS-CoV, which contains a minimal furin-cleavage site consensus sequence in the S protein immediately upstream of the FP, was negatively affected by inhibition of furin, but not of lysosomal proteases.

Results

RNAi mediated gene silencing identifies endocytosis-associated proteins to be important in MHV infection

In an automated, high-throughput RNAi screen [50] targeting the druggable genome (approximately 7000 genes) a number of proteins associated with endocytosis were found to be required for efficient infection of HeLa cells with GFP-expressing MHV. To validate these findings these proteins were subjected to a follow-up analysis using siRNA-mediated gene silencing with oligonucleotides from a different supplier than the one used for the initial RNAi screen (Fig. 1A). The follow-up analysis included ACTR2 and ACTR3, two major constituents of the Arp2/3 complex which are important for the formation of actin branches and cell surface protrusions, as well as for the motility of several pathogens inside host cells (reviewed in [51,52]). Also selected were the RAS-related GTP-binding protein family members, RAB7A and RAB7B, which have been shown to be involved in endosomal maturation (reviewed in [53]). RAB7 interacts amongst others with members of the homotypic fusion and vacuole protein sorting (HOPS) tethering complex, involved in late endosome to lysosome maturation. The HOPS subunit VPS39 (reviewed in [54]) was also found to be a strong hit in the siRNA screen and therefore selected. Other proteins included SNX1, involved in retrograde transport of cargo between endosomes and the trans-Golgi network (reviewed in [55]), VGL, inter alia involved in connecting the Arp2/3 complex with integrins during actin polymerization (reviewed in [56]), and the Ser/Thr-protein kinase PAK1, which is activated by the Rho/Rac/Cdc42 family and is implicated in a variety of downstream effects including modulation of the actin cytoskeleton (reviewed in [57]).
Transfection of HeLa cells carrying the receptor for MHV (HeLa-mCC1a cells) with different siRNAs was followed by an infection with GFP-expressing MHV (MHV-EGFPm) at low multiplicity of infection (MOI), resulting in approximately 10–15% infected cells under control conditions. After 8 h of infection cells were collected and GFP expression by the replication of MHV was analyzed by fluorescence-activated cell sorting (FACS). As controls siRNAs silencing GFP and negative-control siRNAs were used. A hit from the screen was considered as confirmed when transfection with at least two out three independent siRNAs resulted in significant reduction in MHV-driven GFP expression relative to the negative-control siRNAs. siRNA-mediated gene silencing of ACTR2 and ACTR3 resulted in reduced infections for all three siRNAs, indicating that actin branching is important for MHV infection (Figure 1A, dark orange). Also the importance of the RAB7A, RAB7B and VPS39 proteins, involved in late-endosome and late-endosome to lysosome maturation, for MHV infection could be confirmed (Figure 1A, dark orange). The importance of SNX1, VCL and PAK1 for infection of HeLa cells with MHV could not be confirmed (Figure 1A, grey). The latter three genes were not studied any further. To validate our transfection protocol and confirm the efficacies of the siRNAs at the mRNA level, quantitative RT-PCR analysis was performed. All siRNAs used reduced the corresponding mRNA levels with 75–95% (Figure 1B). siRNAs targeting RAB7A were shown to inhibit the expression of a RAB7a-fusion protein (Figure S1 in Text S1).

To confirm and extend our understanding of the role of endocytosis in MHV entry we subsequently selected a number of proteins known to be involved in either caveolae- or clathrin-mediated endocytosis, actin- or microtubule-mediated transport, as well as proteins associated with endosomal vesicles and endosomal maturation, to be screened using the siRNA silencing-approach described above. Again, proteins were considered important for infection with MHV when transfection with at least two out three independent siRNAs resulted in significant reduction in MHV-driven GFP expression relative to the negative-control siRNAs. siRNA-mediated downregulation of proteins involved in caveolae-mediated endocytosis revealed that CAV2, but not the other proteins analyzed are important for infection with MHV (Figure 1C, light blue). Downregulation of most proteins associated with clathrin-mediated endocytosis inhibited MHV infection,
Endocytosis-affecting agents indicate clathrin-mediated endocytosis and endosome maturation to be important in MHV infection

To further explore the endocytic route and factors involved in MHV infection we determined the effect of inhibitors on MHV infection. HeLa-mCC1a cells were treated with endocytosis-affecting agents for 30 min and then infected with luciferase-expressing MHV (MHV-EFLM; [59]) in presence of the inhibitors, after which the inhibitors were kept present until cell lysis. When cells were inoculated with MHV-EFLM in the absence of inhibitors, the inhibitors were added to the cells at 2 h post infection (hpi) to assess effects of inhibitors on post-entry steps. At 7 hpi cells were lysed and firefly luciferase expression levels were determined.

Infection in the presence of the solvents dimethyl sulfoxide (DMSO) and methanol (MeOH), as well as the known inhibitors of MHV RNA synthesis Brefeldin A (BrefA; inhibitor of GBF1) [60] and MG132 (proteasome inhibitor, probably also affects MHV entry; [61]) were included as controls. MHV infection was not affected by addition of the solvents, whereas both MG132 and BrefA severely decreased luciferase expression regardless of the time of addition. Inhibition of endosome maturation with ammonium chloride (NH4Cl), Bafilomycin A1 (BafA1), or Chloroquine (Chloq) severely diminished luciferase expression when the inhibitors were added prior to infection. Much smaller effects were observed when these drugs were added at 2 hpi, indicating that the inhibitors mainly affect MHV entry (Figure 2, dark blue). Similar effects were observed with known inhibitors of clathrin-mediated endocytosis; Chlorpromazine (Chlopro), Monensin (Mon), Dynasore, and Dyngo-4A (Dyngo). All these compounds strongly decreased MHV replication-mediated luciferase expression when added early but not when added at 2 hpi (Figure 2, dark blue). The actin- and macroincocytosis-affecting drug EIPA, which inhibits the Na+/H+ exchanger NHE1, led to reduced luciferase expression both when added prior to and after entry of MHV at 2 hpi. Actin cytoskeleton altering drugs Latrunculin A (LatA), Jasplakinolide (Jasp), Cytochalasin B (CytoB), and Cytochalasin D (CytoD), or the inducer of microtubule depolymerization Nocodazole (Noc) only decreased MHV infection when added early, indicating a role for the actin and microtubule cytoskeleton in entry but not RNA replication (Figure 2, dark orange and orange). Likewise U18666A, a cholesterol transport-affecting agent, which also prevents maturation of late endosomes [62], had a strong inhibitory effect on MHV infection when added early (Figure 2, turquoise). Collectively, these results indicate an important role for clathrin-mediated uptake and for endosome- and endosome-to-lysosome maturation for MHV infection.
Figure 3. Clathrin-mediated endocytosis and late endosome-to-lysosome trafficking is required for MHV fusion. A) Fusion assay upon siRNA-mediated gene silencing. Three different siRNAs per gene were transfected individually into HeLa-mCC1a-Dmi15. 72 h post transfection, cells were pre-loaded with FDG by hypotonic shock. MHV
N was allowed to bind to the cells on ice at MOI = 20 for 90 min. 100 min post warming to 37 °C, cells were collected and analyzed by FACS. Fusion was determined relative to the number of FIC-positive cells observed upon mock treatment of infected cells (UNTR). Error bars represent SEM, n = 3. B) Fusion of MHV upon treatment of cells with different inhibitors was studied as in A. Cells were pretreated with ammonium chloride (NH4Cl), Bafilomycin A1 (BafA1), Chloroquine (Chloq), Chlorpromazine (Chlopro), Monensin (Mon), Dynasore, Dyngo-4A, EIPA, Latrunculin A (LatA), Jasplakinolide (Jasp), Cytochalasin B (CytoB), Cytochalasin D (CytoD), Nocodazole (Noc), U18666A, MG132, Brefelding A (BrefA), as well as with the solvents dimethyl sulfoxide (DMSO) and methanol (MeOH), protein synthesis inhibitor cycloheximide (CHX), and MHV fusion inhibitor HR2 peptide (HR2) for 30 min at 37 °C. The inhibitors were kept present during binding of MHV-N to cells and during warming to 37 °C cells for 100 min. Fusion was determined relative to the number of FIC-positive cells after mock treatment (UNTR). Error bars represent SEM, n = 3.

doi:10.1371/journal.ppat.1004502.g003

In the presence of the agents, and analyzed by FACS as described above. As controls we included protein synthesis inhibitor cycloheximide (CHX), MHV fusion inhibitor peptide HR2 (HR2, [20]), MG132 and BrefA. Fusion of MHV was not affected by the solvents or CHX, the latter confirming that this assay is independent of RNA replication and protein synthesis. MHV fusion was barely affected by replication inhibitor BrefA, whereas MG132 had a clear negative effect, in agreement with the conclusion drawn previously that MG132 inhibits entry of MHV as well as RNA synthesis [61]. Inhibition of endosomal maturation by NH4Cl, BafA1 and Chloq (Figure 3B, deep sky blue) or of clathrin-mediated endocytosis by Chlopro, Mon, and Dynasore (Figure 3B, dark blue) severely inhibited MHV fusion. Disturbance of the actin cytoskeleton by EIPA or by LatA, CytoB, or CytoD reduced fusion by 75–80% (Figure 3B, dark orange), while interference with microtubule polymerization by Noc had a smaller effect (Figure 3B, orange). Late endosomal maturation arrest caused by U18666A reduced fusion to approximately 10% (Figure 3B, turquoise). In conclusion, the replication-independent fusion assay confirmed the importance of clathrin-mediated endocytosis and of endosome maturation for entry of MHV. The data indicate that late endosome-to-lysosome maturation is required for efficient entry and fusion.

Live-cell microscopy confirms co-localization, co-tracking and fusion of MHV in endosomal compartments

To confirm the importance of endocytic uptake and the association of MHV with endosomal compartments we performed live-cell confocal microscopy. To this end, succrose density gradient-purified MHV virus was covalently labeled with the low-pH resistant dye DyLight 488 (MHV-DL488). HeLa-mCC1a cells were transfected with plasmids to express monomeric RFP (mRFP) fusion proteins of RAB5, RAB7, or LAMP1. At 24 h post transfection, MHV-DL488 was bound to cells at 4 °C for 90 min. Inoculation medium was replaced by warm medium containing trypan blue, which immediately shifts the emission spectrum of surface bound particles rendering them undetectable in the 505–530 nm channel unless they get endocytosed [65]. Cells were imaged using a spinning-disc confocal microscope acquiring z-stacks in 30 s intervals over 10 min time frames from 10–70 min post warming. Only low-level RFP fusion protein expressing cells were selected for analysis. Interestingly, MHV particles newly appeared even 60 min post warming, in agreement with the notion that MHV enters in an unsynchronized manner (unpublished results). Co-localization and co-trafficking of viruses with endosomal compartments was assessed by detecting virus particles based on size and intensity (green channel) and by measuring the underlying intensity in the red channel (endosomal vesicles). MHV virions were found to co-localize with all three endosomal compartments (Fig. 4A). Whereas newly entering/appearing particles were always co-localizing with RAB5 molecules, they only associated with RAB7 and LAMP1 containing vesicles at later time points.

To assess the association of MHV with endosomal vesicles during the entry process more extensively, we manually tracked the virus particles in the green channel and independently tracked the endosomal vesicles in the red channel in x/y and z-direction. A virion was categorized as associating/dissociating. Complete disappearance of a virus particle (including in other z-stacks) while immediately previously co-localizing with an endosomal marker was categorized as a
fusion event (Figures S3 and S4 in Text S1). When a viral particle co-localized with endosomal compartments but did neither dissociate nor fade during the 10 min acquisition period it was classified as non-fusing. With this quantification method we analyzed 75–100 virions in total for each of the endosomal compartment types studied. The fraction of virions not fusing during the acquisition period was consistently found to be around 10–15%. We observed that all of the entering MHV particles initially co-localized with RAB5-positive early endosomal vesicles and that most virions dissociated (were no longer co-localized) after 4–6 min. Notably, it appeared that in these events the RAB5 marker faded rather than moved away. Only a very small percentage of virions were categorized as fusing while in early endosomes. The number of fusion events was much higher for virions co-localizing with RAB7 or LAMP1 (Figure 4B), indicating that most virions fuse in late endosomes or lysosomes.

MHV infection depends on endosomal maturation

Our results so far indicate that most virions enter cells after having accessed late endosomes/lysosomes. We hypothesized that these compartments provide the environmental cues required for productive virus-cell fusion. In order to analyze to what extent the low pH in the endosomal system is required for entry of MHV, we analyzed the inhibition of MHV entry at different concentrations of BafA1. While high concentrations of BafA1 (as used for the results shown in Fig. 2 and 3) affect endosomal maturation, at low concentrations this inhibitor of vacuolar-type H^+\text{-ATPase} only elevates the pH of endosomal compartments but does not affect endosomal trafficking per se [66]. We made use of that property and tested the sensitivity of MHV to BafA1 side by side with the control viruses VSV and IAV. VSV has been described to fuse at pH 6.2 in early and/or late endosomes [9,11,12,67–69], while IAV has been shown to fuse in late endosomes at an even lower pH [9,10,70]. HeLa or HeLa-mCC1a cells were pretreated with increasing concentrations of BafA1 for 30 min prior to infection with reporter gene expressing viruses: VSV (VSV\text{D\text{G}/FLuc-G}; [71,72]), IAV (IAV-RLuc; [73]), or MHV (MHV-EFLM). Luciferase expression levels indicated that infection of cells with VSV and IAV is much more affected by BafA1, with an IC50 values of 0.80 and 0.63 nM, respectively, compared to MHV, which displays a three to four fold higher IC50 of 2.34 nM (Figure 5A).

Our results thus indicate that MHV is much less affected by perturbation of the endosomal pH than VSV and IAV. Nevertheless RNAi-mediated silencing of HOPS subunits and treatment of cells with U1866A indicates that late endosome-to-lysosome maturation is required for efficient entry. To confirm
and extend these observations, we made use of haploid HAP1 cells lacking a functional HOPS complex resulting from lentiviral-mediated knockout of the VPS33A subunit (H1-ΔV33 cells; [74]). Both HAP1 cells and H1-ΔV33 cells were modified to stably express the MHV receptor. As a control, the H1-ΔV33 cells were in addition stably transfected with FLAG-tagged VPS33A (H1-ΔV33-V33). The different cells expressed similar levels of the MHV receptor as determined by FACS analysis (Figure S5 in Text S1). Expression of FLAG-VPS33A was confirmed by Western blot (Figure S6 in Text S1). Functional reconstitution was confirmed by confocal fluorescence imaging of lysosome localization (Figure S7 in Text S1). While in the knockout cells the lysosomes were clustered, the lysosomes were dispersed again throughout the cytoplasm in the FLAG-VPS33A re-transfected cells, as observed in the HAP1 parental cells. The haploid cells were infected with luciferase reporter gene-expressing MHV, VSV, or IAV at low MOI. Cells were lysed at 7 (MHV and VSV) or 16 (IAV) hpi and luciferase expression levels were determined. The lack of a functional HOPS complex had no effect on VSV and IAV infection; however, MHV infection was strongly reduced in the knockout, but not in the re-transfected cells (Figure 5B); These observations confirm the conclusion that late endosome-to-lysosome maturation is required for efficient entry of MHV, a characteristic that is not shared with the pH-sensitive VSV and IAV.

Inhibition of lysosomal proteases prevents MHV fusion

Considering that MHV was much less affected by perturbation of the endosomal pH than IAV and VSV while it requires trafficking to lysosomes for efficient entry, we hypothesized that entry might depend on cleavage of a viral protein by lysosomal proteases. Hence we analyzed the extent to which different protease inhibitors could inhibit MHV entry. Thus, HeLa-mCC1a-ΔM15 cells were pretreated for 30 min with the different inhibitors, after which the cells were inoculated with MHV-2N in inhibitor-containing medium. Cells were collected, loaded with FDG, and FDG conversion to FIC by complementation of β-galactosidase upon viral fusion was assayed by FACS. Our results indicate that most protease inhibitors tested (Fig. 6) hardly inhibited fusion of MHV, if at all. Exceptions were AEBSF, which has been shown to cause aggregation of early endosomal vesicles [75], and a pan-lysosomal protease inhibitor (CPI; cystatin-peptatin inhibitor) capable of inhibiting the three major protease family members found in lysosomes. Thus, by using CPI we measured the combined effects of an endosomal papain-like cysteine protease inhibitor (PLCIP), an aspartyl protease inhibitor, and an asparagine endopeptidase inhibitor (AEIP) [76]. From these results we conclude that inhibition of a broad range of endosomal proteases efficiently blocks fusion of MHV, indicating that efficient entry requires the activity of lysosomal proteases.

Introduction of a furin cleavage site immediately upstream of the fusion peptide renders MHV independent of lysosomal proteases

In general, I fusion proteins require cleavage just upstream of the FP to render them fusion competent [20,38,77]. However, while the S protein of MHV is cleaved at the S1/S2 boundary (Fig. 7A), no protease cleavage site has been identified close to the fusion peptide. In view of the inhibition of MHV entry by the pan-lysosomal protease inhibitor CPI and in analogy to other class I fusion proteins, we hypothesized that an additional cleavage in the S protein, immediately upstream of the FP, is necessary to induce fusion. To test this hypothesis, we introduced an optimal furin cleavage site (FCS) by substituting three amino acids by Arg (AIRGR→RRRRRR) immediately upstream of a highly conserved Arg (indicated in bold) that occurs just N-terminal of the FP. Recombinant MHV carrying this FCS in its S2 subunit was designated MHV-S2‘FCS. (Figure 7A). Western blot analysis of the S protein of a purified stock of this virus using an antibody recognizing the S2 subunit showed no evidence of cleavage at the newly introduced FCS (S2‘ site). Apparently, cleavage at this position does not occur during virus production (Figure S8 in Text S1). MHV carrying wild type or mutant S proteins displayed similar growth kinetics (Figure S9 A and B in Text S1). Next we analyzed whether the introduced FCS affected the sensitivity of the recombinant MHV to CPI, which does not exhibit inhibitory activity towards furin. Thus, HeLa-mCC1a cells were pretreated with CPI for 30 min and subsequently infected with wild type S (MHV-EFLM) or mutant S (MHV-S2‘FCS) containing viruses expressing luciferase reporter genes in the presence of the protease inhibitor. At 7 hpi the cells were lysed and viral-replication dependent luciferase expression levels were determined. Introduction of the FCS resulted in the recombinant virus being no longer sensitive to inhibition by lysosomal proteases (Figure 7B), probably because the S protein is now cleaved by furin in an endocytic compartment.

Furin inhibitor renders MHV-S2‘FCS sensitive to endosomal maturation and decreases infection

To confirm that MHV-S2‘FCS is no longer dependent on cleavage by lysosomal proteases, and to study its presumed dependence on furin cleavage for entry, we analyzed the ability of MHV-S2‘FCS to infect the haploid cells that lack VPS33A - and thus the functional HOPS complex required for late endosome-to-lysosome maturation - in the absence or presence of furin inhibitor (FI). After pretreatment of MHV receptor-expressing HAPI, H1-ΔV33, and H1-ΔV33-V33A cells with furin inhibitor (FI) or mock treatment, cells were inoculated with MHV-EFLM or mutant virus MHV-S2‘FCS in presence or absence of FI. At 7 hpi the cells were lysed and viral-replication dependent luciferase expression levels were determined. In agreement with previous results (Fig. 5), infection with MHV carrying a wild type S was severely reduced in cells lacking a functional HOPS complex and addition of the FI did not alter this effect (Figure 8, red bars). In contrast, infection with MHV-S2‘FCS was not decreased by the lack of a functional HOPS complex. However, FI treatment had a clearly

Figure 6. Inhibition of lysosomal proteases prevents MHV fusion. The MHV fusion assay was performed on HeLa-mCC1a-ΔM15 cells as described in the legend to Figure 3, in the presence of the protease inhibitors CPI, AEBSF, Aprotinin, Leupeptin, Pepstatin A, Camostat, and Phosphoramidon. As controls, cells were treated with solvent DMSO, MHV fusion inhibitor HR2 peptide (HR2), and lysosomotropic agent ammonium chloride (NH4Cl). Fusion was determined relative to the number of FIC-positive cells after mock treatment (UNTR). Error bars represent SEM, n = 3. doi:10.1371/journal.ppat.1004502.g006
Haploid HAP1 cells (HAP1), haploid cells lacking VPS33A (H1-ΔV33) or VPS33A-lacking haploid cells transfected with FLAG-tagged VLP33A (H1-ΔV33-V33) were infected (MOI = 0.2) with MHV-EFLM (MHV-wt) or MHV-S2’FCS for 7 h. Where indicated, cells were treated with furin inhibitor (FI). Infection levels were determined by measuring the luciferase activity in cell lysates relative to mock-treated cells. Error bars represent SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g007

negative effect on this virus, which was much more dramatic in the absence of a functional HOPS complex in H1-ΔV33 cells (Figure 8, blue). In conclusion, MHV-S2’FCS lost the requirement for a functional HOPS complex in parallel with this virus becoming insensitive to the pan-lysosomal protease inhibitor CPI. In contrast to the virus with the wild type S, the mutant virus became sensitive to inhibition of furin cleavage.

Figure 8. Furin inhibitor reduces infection with MHV-S2’FCS and renders the virus sensitive to endosomal maturation. Haploid HAP1 cells (HAP1), haploid cells lacking VPS33A (H1-ΔV33) or VPS33A-lacking haploid cells transfected with FLAG-tagged VLP33A (H1-ΔV33-V33) were infected (MOI = 0.2) with MHV-EFLM (MHV-wt) or MHV-S2’FCS for 7 h. Where indicated, cells were treated with furin inhibitor (FI). Infection levels were determined by measuring the luciferase activity in cell lysates relative to mock-treated cells. Error bars represent SEM, n = 3*3.
doi:10.1371/journal.ppat.1004502.g008

MHV-S2’FCS fuses in early endosomes

To explore MHV-S2’FCS entry requirements further, we assessed the effect of RNAi-mediated downregulation of early and late endosome and HOPS complex associated genes. Therefore, HeLa-mCC1a-AM15 cells were transfected with each of three different siRNAs per gene for 72 h, after which they were infected with wild type (MHV-EFLM) or mutant (MHV-S2’FCS) S protein containing MHV. At 7 hpi the cells were lysed and viral-replication dependent luciferase expression levels were determined. As found previously (Fig. 1), infection with wild type S protein carrying MHV was reduced after gene silencing of RAB5, RAB7, VPS11, and VPS41 (Figure 9, red bars). On the other hand, infection with MHV-S2’FCS was significantly diminished by downregulation of the early endosomal proteins RAB5B and RAB5C, but not of the late endosomal proteins RAB7A and RAB7B or the HOPS complex components VPS11 and VPS41 (Figure 9, blue bars). Consistently, infections with MHV carrying wild type or mutant S protein were equally blocked by inhibitors of clathrin-mediated endocytosis whereas the virus with the mutant S (MHV-S2’FCS) was much less sensitive to inhibitors of endosomal maturation, including BaF1, or to perturbants of the actin cytoskeleton (Figure S10 in Text S1). From these results we conclude that introduction of a FCS immediately upstream of the FP abolishes the requirement for trafficking of virions to lysosomes and for processing by lysosomal proteases. The resulting virus, which still depends on clathrin-mediated endocytosis, now requires furin cleavage for efficient entry, the enzymes for which occur earlier in the endocytic pathway [78].

Entry of other CoVs

Our results indicate that the protease cleavage site upstream of the spike protein FP is an important determinant of the intracellular site of fusion. To gain more insight into the putative protease cleavage sites in the corresponding region of the S proteins of other CoVs, we analyzed the sequence of this region in several alpha, beta and gamma coronaviruses by performing ClustalW sequence alignment. The fusion peptide sequence was found to be highly conserved amongst the different coronaviruses. Also an Arginine residue immediately upstream of the predicted fusion peptide is highly conserved with the exception of FIPV (serotype II). Interestingly, MERS-CoV and IBV-Beaudette contain a minimal furin cleavage site Arg-X-X-Arg just upstream of the FP. Thus, we conclude that introduction of a FCS immediately upstream of the predicted fusion peptide renders MHV independent of lysosomal protease activity, while the viral fusion peptide is sufficient to confer entry into early endosomal compartments and facilitate viral replication.
of the fusion peptide (Figure 10A). In analogy with the results obtained with FCS-mutant MHV, we predicted that FIPV and MERS-CoV would differ in their protease inhibitor sensitivity and lysosomal trafficking requirements. To corroborate these findings, we decided to analyze the entry of these two other coronaviruses.

To this end, HeLa cells expressing the FIPV receptor (HeLa-fAPN cells) were subjected to siRNA-mediated downregulation of late endosomal proteins RAB7A and RAB7B or of HOPS complex subunits VPS11, VPS41, and VPS39, followed by inoculation with luciferase expressing FIPV (FIPV-D<sub>3abc</sub>RLuc). At 72 h post transfection, Hela-fAPN cells were inoculated at MOI = 0.2 with luciferase expressing FIPV-RLuc. At 7 hpi infection was determined by measuring the luciferase activity in cell lysates and displayed relative to mock treated infection (inf). Error bars represent SEM, n = 3*3. Dotted line shows the lower 95% confidence interval of the negative siRNA controls. C) HeLa-fAPN cells inoculated with FIPV-RLuc at MOI = 0.1 were treated with pan-lysosomal protease inhibitor (CPI) or furin inhibitor (FI) from 30 min prior to 7 h post inoculation (0–7 h) or from 2–7 h post inoculation (2–7 h; hatched bars). Infection levels were determined by measuring the luciferase activity in cell lysates relative to mock-treated cells. Error bars represent SEM, n = 3*3.

doi:10.1371/journal.ppat.1004502.g010

Figure 10. Entry of FIPV. A) Clustal W alignment of spike proteins from several coronaviruses. Displayed is the fusion peptide (boxed) and the area upstream thereof. The area immediately upstream of the fusion peptide that contains the optimal FCS site (RRRRR) in MHV-S2’FCS is also boxed. B) siRNA-mediated gene silencing was performed as described in the legend to Figure 1. At 72 h post transfection, Hela-fAPN cells were inoculated at MOI = 0.2 with luciferase expressing FIPV-RLuc. At 7 hpi infection was determined by measuring the luciferase activity in cell lysates and displayed relative to mock treated infection (inf). Error bars represent SEM, n = 3*3. Dotted line shows the lower 95% confidence interval of the negative siRNA controls. C) HeLa-fAPN cells inoculated with FIPV-RLuc at MOI = 0.1 were treated with pan-lysosomal protease inhibitor (CPI) or furin inhibitor (FI) from 30 min prior to 7 h post inoculation (0–7 h) or from 2–7 h post inoculation (2–7 h; hatched bars). Infection levels were determined by measuring the luciferase activity in cell lysates relative to mock-treated cells. Error bars represent SEM, n = 3*3.

doi:10.1371/journal.ppat.1004502.g010

Discussion

The results of this study provide an explanation for several, apparently conflicting results from earlier studies with respect to the process of MHV cell entry, particularly also regarding the necessity of proteolytic cleavage of the CoV S protein. By using a replication-independent fusion assay, we confirmed that MHV entry requires clathrin-mediated endocytosis despite the well-known ability of the MHV S protein to cause cell-cell fusion at neutral pH. We demonstrate that MHV particles traffic to and fuse in lysosomes. Yet, MHV is much less sensitive to perturbation of the low pH in the endo-/lysosomal system than low pH-dependent control viruses VSV and IAV. Our results additionally indicate that, for fusion to occur, the S protein of MHV requires
Proteolysis-Dependent Coronavirus Entry via an Endo-/Lysosomal Pathway

Proteolytic cleavage immediately upstream of the FP, like other class 1 fusion proteins. Efficient inhibition of MHV entry was only observed using a pan-lysosomal protease inhibitor, and could not be achieved using more specific protease inhibitors. Introduction of an optimal furin cleavage site in the S protein immediately upstream of the FP abolished the requirement for trafficking of virions to lysosomes for fusion. However, this virus still required clathrin-mediated uptake for efficient entry. Consistent with a common mechanism for the entry of CoVs, FIPV, but not MERS-CoV, the latter of which contains a furin cleavage site immediately upstream of the FP, was shown to require trafficking to lysosomes and processing by lysosomal proteases for efficient entry. Based on these results we propose a model in which the cleavage site immediately upstream of the FP is an essential determinant of the intracellular site of CoV fusion (Figure 12).

The importance of clathrin-mediated endocytosis and endosomal trafficking in the entry of MHV was revealed by several complementary approaches. One of these was siRNA-mediated gene silencing. Although - with the exception of RAB7A - knockdown was not monitored at the protein level, we believe this approach firmly demonstrates the importance of novel host factors for several reasons. Validated siRNAs were used and the experimental conditions were confirmed by analyzing the mRNA expression levels of several genes by quantitative RT-PCR. Furthermore, we made use of three independent siRNAs per target gene, and a target was only classified as a hit when at least two out three siRNAs showed the same phenotype. Importantly, our findings were strengthened by targeting multiple proteins per host cell pathway/complex, each time with very similar results. Moreover, hits obtained with the replication-dependent reporter assays were confirmed with our novel replication-independent enzyme complementation entry assay. Also the use of recombinant viruses differing only in their spike proteins enabled us to show that inhibition of virus infection upon siRNA transfection resulted from differences in virus entry and not virus replication. Finally, the results obtained were corroborated by using a large panel of inhibitors and by making use of haploid knockout cells, in which late endosome-to-lysosome trafficking was inhibited.

Our results demonstrate that MHV requires endocytic uptake for virus entry despite the S protein's ability to induce cell-cell fusion at neutral pH. Endocytic uptake is also required for a mutant virus carrying a S protein with a FCS immediately upstream of its FP, despite the relative insensitivity to high concentrations of BafA1. Therefore, the ability of a virus to infect cells in the presence of BafA1 does not necessarily imply virus entry to occur at the cell surface. Also a recombinant MHV carrying the spike protein of MHV-4 (MHV-JHM) was found to enter via clathrin-mediated endocytosis (MHV-S4; Figure S10 in Text S1) despite its ability to cause extensive cell-cell fusion [80–82]. The ability of MHV to cause cell-cell fusion at neutral pH while requiring endocytic uptake for virus-cell fusion suggests different requirements and triggers for these two fusion processes. Similarly, RSV was recently shown to enter cells after endocytic uptake despite the ability of this virus to cause cell-cell fusion [13].

The present study confirms and extends previous publications on MHV entry via clathrin-mediated endocytosis [26,83]. Both siRNAs downregulating clathrin-mediated endocytosis-associated proteins, such as clathrin heavy chain (CLTC) and Dynamin 2 (DNM2), and agents affecting this uptake pathway (Chlopro, Dynasore, Dynago-4a) were capable of inhibiting infection with MHV. Importantly, these findings could be confirmed in our novel replication-independent virus-cell fusion assay, thereby directly showing an involvement of clathrin-mediated endocytosis in entry of MHV. Analysis of several accessory factors of clathrin-mediated endocytosis showed that clathrin-mediated entry of MHV strain A59 depends on clathrin-adaptor DAB2, but not on EPS15 or AAK1. Previously, clathrin-mediated entry of MHV strain 2 was also shown to be independent of EPS15 [83]. Based on the use of inhibitors, it was earlier concluded that MHV entry depends on cholesterol and lipid-rafts, which may be indicative of caveolae-mediated endocytosis [84,85]. Although our replication-dependent assays indicate a requirement for caveolin 2 (CAV2) for infection, this protein was shown not to be involved in virus entry using our fusion assay. Also depletion of other proteins involved in caveolae-mediated endocytosis, including caveolin 1 (CAV1) and flotillins 1 and 2 (FLOT1 and FLOT2) did not affect MHV infection or fusion. Interestingly, fusion of MHV was severely inhibited by EIPA, an inhibitor of the Na+/H+ exchanger NHE1, which is regarded as a hallmark inhibitor of macropinocytosis. Apparently, inhibition of virus entry by EIPA does not prove by itself that a virus enters via this particular pathway. EIPA has been reported to affect several other cellular processes, including actin remodeling, internalization of lipid rafts, distribution of endosomes, and even clathrin-mediated endocytosis [86–90]. Similar to the results obtained with the HeLa cells, also infection of murine LR7 cells was inhibited by compounds interfering with clathrin-mediated endocytosis (Figure S11A in Text S1).

MHV virions require trafficking through the endocytic pathway to lysosomes for efficient entry. Upon clathrin-mediated uptake these virions are temporarily associated with early endosomes as demonstrated by co-localization with Rab5 during live cell imaging. Furthermore, the importance of early endosomes for entry was indicated by siRNA-mediated downregulation of various proteins associated with early endosomes (EEA1, Rab5A, Rab5B, and Rab5C), which inhibited MHV infection, as well as virus-cell fusion. However, only very few MHV particles appeared to fuse in the early endosomes. Live cell imaging indicated fusion largely to occur in late endosomes and/or lysosomes. Consistently, depletion of host proteins associated with late endosome and late endosome-to-lysosome maturation (RAB7A, RAB7B, and the HOPS complex subunits VPS11, VPS35A, VPS39 and VPS41) or addition of U18666A, which blocks late endosome-to-lysosome trafficking, were shown to inhibit both infection and virus-cell fusion. The importance of lysosomes for entry was confirmed by using knockout cells lacking a functional HOPS complex [54]. Interestingly, in these cells lysosomes are clustered in a
perinuclear region of the cell rather than dispersed throughout the cytoplasm. Complementation of the missing HOPS subunit restored the normal lysosome distribution and entry of MHV (Figure S7 in Text S1). The importance of late endosome-to-lysosome trafficking for efficient entry was also observed in murine cells (Figure S11C in Text S1) and for MHV-S4 carrying the S protein of MHV-4 (JHM; Figures S10 and S12 in Text S1).

Corroborating the importance of trafficking of MHV virions through the endocytic pathway, perturbation of endosome maturation by the addition of inhibitory agents, such as ammonium chloride, BafA1, Chloroquine, and Monensin inhibited infection and fusion of MHV. Also the importance of the actin and microtubule cytoskeleton - as demonstrated by the inhibition of MHV entry by downregulation of the Arp2/3 complex factors (ACTR2 and ACTR3), of the microtubule-associated transporter dynein (DYNClH1 and DYNC2H1), or by addition of actin- or microtubule-affecting drugs - may be explained by the documented involvement of the cytoskeleton in endosome maturation [7]. Indeed, entry of MHV-S2'FCS, which presumably fuses in early endosomes, was much less affected by actin-affecting drugs than that of MHV carrying wild type spike proteins (Figure S10 in Text S1). However, we cannot exclude that actin also plays a role in the clathrin-mediated uptake of MHV particles, as has been observed for VSV and other pathogens that depend on clathrin-mediated endocytosis (reviewed in [91]).

MHV particles require trafficking to the low pH environment of lysosomes to achieve membrane fusion. Nevertheless, MHV was much less sensitive to elevation of pH in the endo-/lysosomal system by the addition of BafA1 than viruses known to fuse in early or late endosomes (VSV and IAV). BafA1, an inhibitor of vacuolar-type H\(^+\)-ATPase was effective in blocking MHV entry only at high concentrations, which are known to prevent endosomal maturation in addition to the elevation of the pH [66]. The absence of a functional HOPS complex, which is required for late endosome-to-lysosome maturation, did not affect infection of cells with VSV or IAV, while entry of MHV was severely reduced. Thus, the low pH trigger that mediates entry of VSV and IAV in the endosomal system of these cells, is not sufficient to induce fusion of MHV. Other environmental cues, present in lysosomes only, are apparently required to activate conformational changes in the S protein leading to fusion. Indeed, inhibition of the three major classes of proteases present in the lysosome by CPI effectively prevented MHV fusion. Infection of murine LR7 cells with MHV was also inhibited by CPI (Figure S12C in Text S1).
S11B in Text S1). Strikingly, other inhibitors that affect members of a single protease family had none or only little impact on MHV fusion. These results are in consistence with a functional redundancy of protease family members [47,76] and may explain why previous studies using specific lysosome protease inhibitors [27,92] failed to detect entry inhibition. Also, the inhibition of MHV entry by MG132 may be explained by the known ability of the proteasome inhibitor to negatively affect lysosomal proteases [93–95], although we cannot exclude that MG132 affects entry by its interference with lysosomal trafficking [96].

Our results indicate that cleavage of the S protein immediately upstream of the FP is essential for CoV entry and determines the intracellular site of fusion. Although we did not demonstrate cleavage of MHV S at the FP proximal position directly, a recent study found a cleaved form of the MHV S2 subunit to correspond with the fusion-active form [49]. Furthermore, introduction of an optimal FCS at the FP proximal position abolished the entry inhibition by the pan-lysosomal protease inhibitor whilst introducing a dependency on furin-related enzymes. Consistent with the known presence of active furin in early endosomes [reviewed in [78]] the mutant virus no longer required trafficking to late endosomes/lysosomes for entry to occur. However, in the presence of furin inhibitor, entry of this mutant MHV was much more efficient in wild type cells than in cells lacking a functional HOPS complex (Fig. 8), indicating that under certain circumstances lysosomal proteases may play a role in entry of this virus as well. Trafficking of virions to lysosomes was shown to be also important for entry of FIPV, but not of MERS-CoV, in agreement with the latter virus containing a putative FCS immediately upstream of the FP. Correspondingly, entry of FIPV was inhibited by the pan-lysosomal protease inhibitor CPI but not by furin inhibitor, while the reciprocal held true for MERS-CoV. The importance of S protein cleavage downstream of the S1/S2 boundary and upstream of the FP for infection has so far only been demonstrated for SARS-CoV and IBV [40,43,46-48].

Based on the present study and on the work of others, we conclude that cleavage at the FP proximal position is likely to be a general requirement for CoV entry. With the exception of possibly IBV, cleavage at this position does not appear to occur in the virion-producing cell as it is not observed in released virions, but in the target cell (this study; [40,43,47,48]). This suggests that receptor binding or other environmental cues are necessary to render the cleavage site accessible for proteolysis in the intact virion. Also for several other viruses, including RSV [13] and Ebola virus [16], cleavage of the fusion protein upon endocytosis has been shown to be required for entry. Our results furthermore show that cleavage at a FP-proximal position is an important determinant of the intracellular site of fusion. The question remains, however, why some CoVs evolved to fuse in early endosomal vesicles while others require trafficking to lysosomes. In view of the growing number of proteases that have been shown to cleave CoV spike proteins [97], this question should probably be studied in relation to the proteolytic enzymes available in the CoV target tissues and cells in vivo.

Materials and Methods

Cells and viruses

Marine LR7 fibroblast [98] and feline FCWF cells (ATCC) were used to propagate the recombinant MHV and FIPV viruses, respectively. HEK293T, MDCK and Vero cells were used to propagate pseudotyped VSVΔG/Luc-G*, Renilla luciferase expressing influenza A pseudovirus, or MERS-CoV, respectively, as described previously [71,73,99]. Cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium (DMEM, Lonza), supplemented with 10% fetal bovine serum (FBS). HeLa-ATCC cells stably expressing murine CEACAM1a (HeLa-mCC1a) and LR7 cells were used for infection experiments with MHV. HeLa-mCC1a cells stably expressing the deficient β-galactosidase ΔM15 (HeLa-mCC1a-ΔM15) were used in the fusion assay. Stable cell lines were generated using a Moloney murine leukemia (MLV) retroviral vector. MLV was produced in HEK293T cells by triple plasmid transfection of a transfer vector containing the ΔM15 or mCC1a gene as well as a puromycin or neomycin resistance marker gene, respectively, in combination with expression vectors encoding the MLV Gag-Pol, and the VSV spike protein G. Upon MLV transduction, stably transduced cells were selected at 2 µg/ml puromycin and/or 0.5 mg/ml G418 (both Sigma), maintenance at 1 µg/ml puromycin and/or 0.5 mg/ml G418 in DMEM, supplemented with 10% FBS. HAP1 cells and the VPS33A knockout derivative thereof (H1-ΔV33) have been described previously [74]. H1-ΔV33 cells were stably transfected with FLAG-tagged VPS33A (H1-ΔV33-ΔV33) using MLV transduction as described above using a lactacystin resistance marker gene in the transfer vector. Stable transduced cells were selected and maintained at 5 µg/ml blasticidin. HAP1 cells and its derivatives were also provided with mCC1 as described above to allow infection of these cells with MHV.

Chemicals

The MHV fusion inhibitor HR2 peptide has been described before [100] and was synthesized by GenScript. The peptide was diluted in Tris/HCl 50 mM, pH 7.8, 4 µM EGTA at 1 mM stock solution and used at 10 µM final concentration. Fluorescein-di-β-D-galactopyranoside (FDG) (AnaSpec) was dissolved in DMSO resulting in a 20 mM stock solution. Stocks of 700 mM cycloheximide (CHX, Sigma), 125 mM Bafilomycin A1 (BafA1, Enzo Life Sciences), 140 mM Chloroquine (Chloq, Sigma), 120 mM Dynasore (Dyn, Enzo Life Sciences), 15 mM Dyno4a (Dyno, Abcam), 100 mM Ethylisopropyl amilorid (EIPA, Enzo Life Sciences), 1 mM Nocodazol (Noc, Sigma), 1 mM Latrunculin A (LatA, Enzo Life Sciences), 2 mM Jasplakinolide (Jasp, Sigma), 20 mM Cytochalasin B (CytoB, Sigma), 20 mM Cytochalasin D (CytoD, Sigma), 25 mM GM132 (Sigma), 1 mM Breffeld A (BreA, Sigma), and 10 mM Furin Inhibitor I (FI, Calbiochem) were prepared in DMSO and diluted 1:1000 in the experiments, except when indicated otherwise. Stocks of 2 M ammonium chloride (NH₄Cl, Fluka), 5 mM AEBSF, 5 mM Leupeptin, 1 mM Camostat, 1 mg/ml Aprotinin (all obtained from Sigma) were prepared in H₂O and used at 1:100 final concentrations. 10 mM chlorpromazine (Chlopro, Sigma), and 20 mM U18666A (Enzo Life Sciences) were prepared in H₂O and used at 1:1000 final concentrations. Stocks of 6 mM Nmonensin (Mon, Sigma) and 5 mM Phosphoramidon (Sigma) were prepared in methanol (MeOH) and used at 1:100 and 1:100 final concentrations, respectively. 25 mg/ml cycloheximide (CHX, Sigma) and 5 mM Pepstatin A (Sigma) were prepared in methanol (EtOH) and used at 1:100 and 1:100 final concentrations, respectively. Solvents EtOH, MeOH, and DMSO were obtained from Sigma-Aldrich. A stock of 125 µM CPI in PBS was made [76] and used at 5 µM final concentration.

Plasmids

All plasmids were constructed using conventional cloning techniques. The ΔM15 gene was isolated from a DH5 E. coli strain by DNA extraction and PCR. The gene was cloned into a pCAGGS vector for (transient) expression and into a MLV-based pQCXIP transfer vector (Clontech), resulting pQCXIP-AM15, for
the generation of stable cell lines. The gene encoding the MHV receptor mCC1a [101] was cloned into pQCXIN, resulting in pQCXIN-mCC1a. The RNA transcription vectors used for the generation of recombinant MHV using targeted recombination were generated using pMH54 derivatives [99,102]. pMH54 containing a GFP expression cassette between the E and M gene was generated as described previously for firefly luciferase [59]. The transcription vector used to generate MHV-S2'FCS (pXHERLM-S2'FCS+) was generated by site-directed mutagenesis, thereby changing the sequence encoding AIRGR immediately upstream of the FP into a RRRRR-encoding sequence in vector pXHERLM [59] (GCA/ATC/CGA/GGG/GCT to AGA/CCG/CGA/AGG/GCT). The transcription vector used to generate MHV-S4 expressing firefly luciferase, was generated by introducing the firefly luciferase expression cassette between the E and M genes similarly as described previously [59] in a pMH54-derived transcription vector that contains the gene encoding the S protein of MHV-4 (MHV-JHM) [82]. This latter vector was kindly provided by Susan Weiss.

**Generation of recombinant/pseudo viruses**

Recombinant MHV-EGFPm virus, containing a GFP expression cassette between the E and the M gene, MHV-S2'FCS, containing a *Renilla* luciferase expression cassette between the E and the M gene and a FCS at the FP-proximal position, and MHV-S4 containing the spike gene of MHV-4 (JHM) and a luciferase expression cassette were generated by targeted RNA recombination as described before [98]. Briefly, donor RNA was generated from linearized pMH54-derived transfer vectors described above, and electroporated into FCWF cells infected with interspecies chimeric MHV coronavirus (an MHV-A59 derivative, in which the ectodomain of the spike protein has been replaced by that of a feline coronavirus, thereby changing host cell tropism). The electroporated FCWF cells were seeded onto a monolayer of LR7 cells. After 24 h of incubation at 37°C, culture supernatant containing progeny viruses was harvested. Genotypes of the recombinant viruses were confirmed after two rounds of plaque purifications. Passage 3 stocks were used in experiments. Generation of MHV-EFLM and MHV-ERLM, containing a firefly or *Renilla* luciferase expression cassette between the E and the M gene, and MHV-S2'FCS, containing a N protein tagged with the ω-peptide, has been described before [63,103]. Construction of FIPV expressing *Renilla* luciferase was reported previously [79]. Recombinant VSVΔG/FLuc-G* pseudo-virus was generated as described before [71]. Construction of IAV-WSN pseudovirus expressing *Renilla* luciferase has also been described previously [73]. Viruses were stored in culture medium, supplemented with 25 mM HepES or upon sucrose cushion purification in TN buffer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl).

**siRNA transfections**

30,000 HeLa-mCC1a-(AM15) cells were seeded one day prior to transfection in a 24-well dish. Using Oligofectamine (Life Technologies) reagent three independent, non-overlapping siRNAs (pre-designed Silencer Select siRNAs from Ambion) per gene were individually transfected into target cells according to the manufacturer’s instructions. Transfection mix for one well contained 2.5 μl of 1 μM siRNA and 0.5 μl Oligofectamine in 50 μl OptiMEM (Gibco). Transfection was done in 250 μ1 final volume of OptiMEM. 4 hours post transfection 125 μ1 of DEMEM, 30% FBS were added. Cells were infected 72 hours post transfection.

**qRT-PCR of siRNA-mediated gene knockdowns**

HeLa-mCC1a cells were subjected to siRNA-mediated gene knockdown as described above. At 72 hpi cells were harvested by trypsinization, single-cell suspension counted, and collected by centrifugation. Cellular RNA was extracted using the RNeasy Mini Kit (Qiagen). mRNA levels of genes were analyzed by qRT-PCR using a custom designed pair of specific primers to the gene resulting in about 150 bp products. RNA levels were measured using the GoTaq 1-Step RT-qPCR system (Promega) according to the manufacturer’s instructions on a LightCycler 480 (Roche). Expression levels were corrected for cell number and viability as determined by the Wst-1 assay (Roche).

**Viruses infections**

Cells were inoculated with MHV-EGFPm at MOI = 0.5 [15–20% infected cells] in DEMEM, 2% FBS, for 2 h at 37°C. The inoculum was replaced by warm DEMEM, 10% FBS. At 8 hpi, cells infected with MHV-EGFPm were trypsinized and fixed in 4% formaldehyde solution in PBS. Cells were washed and taken up in FACS buffer (2% FBS, 0.05M EDTA, 0.2% NaN3 in PBS) and GFP expression was quantified by FACS analysis on a FACS Calibur (Benson Dickson) using FlowJo software. Of each sample at least 10,000 cells were analyzed. HeLa, LR7, or HAP1 cells were inoculated with luciferase expressing (pseudo)viruses (MHV-EGFPm, VSVΔG/FLuc-G*, IAV-RLuc, MHV-S2'FCS, or FIPV-RLuc, MHV-EFLM-S4 (JHM)) at MOI = 0.2, unless indicated otherwise, in DEMEM or IMDM (HAP1), supplemented with 2% FBS at 37°C. At 2 hpi the inoculum was replaced by warm medium containing 10% FBS. Cells were lysed at 7 hpi (MHV, VSV, and FIPV) or 16 hpi (IAV) in passive lysis buffer (Promega). Firefly luciferase expression was assessed using the firefly luciferase assay system from Promega or using a homemade system (50 mM tricine, 100 mM EDTA, 2.5 mM MgSO4, 10 mM DTT, 1.25 mM ATP, 12.5 μM D-Luciferin). *Renilla* luciferase expression was assessed using the *Renilla* luciferase assay system (Promega). Light emission was measured on a Centro LB 960 luminometer. When indicated cells were transfected with siRNAs prior to inoculation as described above. Luciferase expression levels (in relative light units, RLU) were corrected for cell number and viability as determined by the Wst-1 assay (Roche). When indicated cells were treated with pharmacological inhibitors starting at 30 min prior to or 2 h post inoculation. Huh-7 cells were inoculated with MERS-CoV at a MOI of 0.1 in FBS-containing DEMEM. 8 h post infection, cells were fixed in 4% formaldehyde in PBS. Cells were stained using rabbit anti-SARS-CoV nsp4 antibodies that are cross-reactive for MERS-CoV, according to a standard protocol using a FITC-conjugated swine-anti-rabbit antibody. Number of infected cells was determined by cell counts on a wide-field fluorescent microscope.

**Fusion assay using β-galactosidase complementation**

The β-galactosidase complementation fusion assay was performed as described previously [63]. Briefly, cells were preloaded with FDG substrate by incubation of adherent target cells with 2.5% FBS, 100 mM FDG, 50% PBS at room temperature. After 5 min incubation an excess of 5% FBS in PBS was added, supernatant removed and replaced by growth medium. After a recovery period of 30 min at 37°C, cells were (mock) treated with the different inhibitors for 30 min. MHV-2n virus was bound to cells in DEMEM with 2%FCS (in the absence or presence of inhibitors) at a MOI = 20 for 90 min at 4°C to synchronize infection, after which cells were shifted to 37°C for 2 h. Cells were trypsinized and transferred to Eppendorf tubes, washed and immediately analyzed by FACS. For experiments with protease inhibitors the cells were loaded with FDG by hypotonic shock after trypsinization and collection of the cells. In this case, FDG loaded
cells were incubated on ice for 14 h before being analyzed by FACs.

**Fluorescent labeling of MHV**

MHV wt virus was grown on L929 cells and purified over a 20% sucrose cushion in TN buffer by centrifugation at 110,000 rcf for 2.5 h. Supernatant was removed and pellet resuspended in 200 μl TN buffer overnight on ice. Concentrated virus solution was subjected to further purification on a Pfefferkorn gradient (10–20%, 25–50%, 50% cushion). After spinning for 1 h at 150,000 rcf a clear virus band was visible. The virus band was collected and diluted in TN buffer. The virus was pelletted by centrifugation at 110,000 rcf for 1 h and resuspended in 200 μl 0.1M sodium phosphate, 0.15M NaCl buffer pH 7.2 overnight on ice. The purified virus solution was labeled using DyLight NHS 488 (Thermo Scientific) according to the manufacturer’s instructions. Infectivity of the labeled virus was confirmed by TCID50 analysis and qRT-PCR.

**Live-cell microscopy**

HeLa-mCCla cells were seeded into 8-well glass-bottom chambers to reach 60% confluency the next day. Plasmids encoding mRFP-tagged RAB5A or RAB7A, or dsRed-LAMP1 [104] were transfected into the cells one day after seeding using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. 24 h after transfection MHV-DyLight488 was bound to cells on ice at MOI = 20 for 1.5 h in DMEM, 2% FBS. The inoculum was removed and cells washed with cold PBS to remove unbound virus. Warm imaging medium (DMEM without phenol red, 10% FCS) containing 0.008% trypan blue (Invitrogen) was added to the cell chambers. The cell membrane impermeable trypan blue shifts the expression spectrum of cell surface bound particles rendering them undetectable in the 505–530 nm channel (described in [65]). Different low to medium RFP expressing cells were imaged live at 37°C, 5% CO₂ in 10 min time frames from 10 min post warming up to 70 min in 30 s intervals thereby acquiring z-stack images. Each slice was 0.30 μm in thickness, averaging 12–14 slices per stack. For recording a Zeiss Axio Observer Z1 inverse spinning-disk confocal microscope, equipped with full box stage incubation, including CO₂ (Pecora), argon-krypton and helium-neon laser, two Photometrics Evolve 512 back-illuminated electron-multiplying charge-coupled-device (EM-CCD) cameras, and 100×1.46NA Oil alpha Plan Apochromat objective was used. Fluorescences images were exported as czi files (Zeiss) and subsequently imported into Fiji (ImageJ, NIH).

Upon import into Fiji, color channels were split and saved as 8-bit tagged image file format. Virus movements were manually tracked in x/y or z direction in the green channel using the MTtrack plugin. Tracks were saved and subsequently loaded onto the red channel. For each virus spot the area underlying a circle of 0.213 μm² was measured for its gray mean value. Viruses were considered colocalizing if the gray mean value reached 50% of the maximum. Subsequently red and blue color channels were merged, tracks imported and viruses classified using the viral track. If the virus co-localized with the endosomal vesicle over at least four sequential 500 micron frames the virus was categorized as associating. Viruses that, after initial co-localization, separated from the vesicle were classified as ‘associating/dissociating’. If a virus particle faded and disappeared (and could not be found in other z-stacks) whilst co-localizing in previous intervals with an endosomal vesicle it was categorized as ‘fusing’ (Figure S3). When a viral particle co-localized with endosomal compartments but did neither dissociate nor fade during the 10 min acquisition period it was classified as ‘non-fusing’. With this quantification method we analyzed 12 cells for RAB5 with 75 virions in total, 12 cells for RAB7 with 105 virions in total, and 16 cells for LAMP1 with 115 virions in total, acquired over three independent experiments.

**Sequence alignment**

The sequences of MHV-A59 and MHV-S2'FCS were based on pMH54 sequencing results. Sequences for BCoV (GI: 18033975), FIPV (GI: 556923469), HCoV-OC43 (GI: 530802591), HCoV-HKU1 (GI: 306569687), SARS-CoV (GI: 89744748), MERS-CoV (GI: 510937295), HCoV-229E (GI: 82780499), HCoV-NL63 (GI: 530802144), IBV-Beaudette (GI: 138186) were obtained from NCBI. Alignments were performed over the entire length of the spike proteins using MegAlign (Lasergene DNASTAR) using a ClustalW alignment, gap penalty 10, gap length penalty 0.2, delay divergent sequences 30%, DNA translation weight 0.5, protein weight matrix: PAM series, DNA weight matrix: ClustalW.

**Confirmation of siRNA-mediated knockdown of RAB7A**

HeLa cells were co-transfected with mRFP-tagged RAB7A similarly as described previously [60]. Briefly, 7,500 HeLa cells were seeded one day prior to transfection in a 96-well plate. Using Oligofectamine (Life Technologies) reagent three independent, non-overlapping RAB7A siRNAs (pre-designed Silencer Select siRNAs from Ambion) per gene were individually transfected into target cells with the mRFP-RAB7A plasmid. Transfection mix for one well contained 2.5 μl of 1 μM siRNA, 10 ng plasmid, and 0.5 μl Oligofectamine in 12.5 μl OptiMEM (Gibco). Transfection was done in 62.5 μl final volume of OptiMEM. 4 hours post transfection 125 μl of DMEM, 30% FBS were added. RFP expression was analyzed 24 h post transfection using an EVOS Cell Imaging System.

**Immunostaining of HAP1 cells**

Confluent HAP1, H1-DV33, and H1-DV33-Iv33 cells and their stably mCeacam1a expressing counterparts were detached using a cell scraper, homogenized, and fixed. After 30 min incubation in blocking buffer (3% BSA, Sigma) in PBS for 1 h cells were incubated in 1:100 N-CEACAM-Fc [80] antibody, washed, and stained with 2× AF488 goat-anti-rabbit antibody (Life Technologies). After washing cells were analyzed by FACs at 10,000 gated single cells per sample.

**Western blotting**

HAP1 cells were trypsinized and collected by centrifugation at 350 rcf for 10 min. The pellet was resuspended in Laemmli sample buffer containing 100 mM DTT, boiled for 5 min at 95°C and subjected to electrophoresis in 10% acrylamide (Bio-Rad) gels. Viruses were purified and concentrated over a 20% sucrose cushion (in TN buffer) at 110,000 rcf. Pelleted virus was resuspended in TN buffer overnight on ice. After addition of Laemmli sample buffer (1× final concentration, 100 mM DTT), samples were boiled for 5 min at 95°C and subjected to electrophoresis in 7% acrylamide (Bio-Rad) gels. Upon transfer to a nitrocellulose membrane (Millipore), the presence of cellular and viral proteins was probed with antibodies against GM130 (rabbit pAb, Abcam), FLAG (HRP-labeled mouse anti-FLAG mAb, Sigma) or the S2 subunit of MHV A59 [105] (mouse anti-S2 mAb) diluted 1:1000. When necessary, the blots were subsequently incubated with HRP-labeled rabbit anti-mouse or swine anti-rabbit antibodies (both diluted 1:5000; DAKO). Binding of HRP-labeled antibodies was visualized using Amersham ECL Western blotting substrate (GE Healthcare Life Sciences) according to the manufacturer’s instructions.
Immunofluorescence analysis of HAP1 cells

To image the localization of LAMP1 in HAP1, H1-AV33, and H1-AV33A-V33, the cells were seeded onto coverslips one day prior to staining. Cells were fixed in 4% formaldehyde in PBS for 15 min at RT, washed with PBS, and subsequently permeabilized in PBS containing 0.1% Triton-X-100 for 10 min. Cells were incubated with antibody against LAMP1 (rabbit anti-LAMP1 pAb, 1:100 dilution; Abcam) in 3% BSA in PBS followed by incubation with secondary antibodies coupled to AF488, AF-568 phalloidin, and DAPI (all Life Technologies). The samples were analyzed using a confocal laser-scanning microscope (Leica SPE-II).

Growth curves of recombinant viruses

LR7 cells were infected at MOI = 0.1 or MOI = 4.0 with MHV-ERLM or MHV-S2’FCS in DMEM containing 2% FBS and 25 mM HEPES (infection medium). After 3 h of infection supernatant was replaced by fresh infection medium and infection was allowed to progress over a period of 24 h. Every 3 h a small sample of the culture supernatant was collected and immediately frozen. The samples were subsequently analyzed in TCID50 assays on LR7 cells and subjected to qRT-PCR analysis to quantify virion production. Therefore viral RNA was extracted from the samples using the QIAamp Viral RNA Mini Kit (Qiagen). The relative amount of viral RNA present was determined with a LightCycler 480 using LightCycler 480 RNA Master Hydrolysis kit (Roche Applied Biosciences) and specific primers and probe targeted against the MHV 1b gene by comparison with a standard curve.

Gene identification numbers

<table>
<thead>
<tr>
<th>Gene</th>
<th>SwissProt ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAK1</td>
<td>Q2M2I8</td>
</tr>
<tr>
<td>ACTR2</td>
<td>P61160</td>
</tr>
<tr>
<td>ACTR3</td>
<td>P61158</td>
</tr>
<tr>
<td>CAV1</td>
<td>Q03135</td>
</tr>
<tr>
<td>CAV2</td>
<td>P11636</td>
</tr>
<tr>
<td>CLTC</td>
<td>Q00610</td>
</tr>
<tr>
<td>DAB2</td>
<td>P98082</td>
</tr>
<tr>
<td>DNM1</td>
<td>Q05193</td>
</tr>
<tr>
<td>DNM2</td>
<td>P55070</td>
</tr>
<tr>
<td>DYN1H1</td>
<td>Q14204</td>
</tr>
<tr>
<td>DYN2H1</td>
<td>Q8NCM8</td>
</tr>
<tr>
<td>EPS15</td>
<td>P42566</td>
</tr>
<tr>
<td>FLOT1</td>
<td>O75955</td>
</tr>
<tr>
<td>FLOT2</td>
<td>Q14254</td>
</tr>
<tr>
<td>LAMP1</td>
<td>P11279</td>
</tr>
<tr>
<td>MY06</td>
<td>Q9UM54</td>
</tr>
<tr>
<td>NSF</td>
<td>P6459</td>
</tr>
<tr>
<td>PAK1</td>
<td>Q13153</td>
</tr>
<tr>
<td>RAB5A</td>
<td>P20339</td>
</tr>
<tr>
<td>RAB5B</td>
<td>P61020</td>
</tr>
<tr>
<td>RAB5C</td>
<td>P51148</td>
</tr>
<tr>
<td>RAB7A</td>
<td>P51149</td>
</tr>
<tr>
<td>RAB7B</td>
<td>Q96AH8</td>
</tr>
<tr>
<td>SNX1</td>
<td>Q13596</td>
</tr>
<tr>
<td>VCL</td>
<td>P18206</td>
</tr>
<tr>
<td>VPS11</td>
<td>Q9H270</td>
</tr>
<tr>
<td>VPS33A</td>
<td>Q96AX1</td>
</tr>
<tr>
<td>VPS39</td>
<td>Q96JC1</td>
</tr>
<tr>
<td>VPS41</td>
<td>P9754</td>
</tr>
</tbody>
</table>

Supporting Information

Text S1 Supporting information. (PDF)

Acknowledgments

We would like to thank Dr. Thijn Brummelkamp, Biochemistry Division, Netherlands Cancer Institute, Amsterdam, The Netherlands, for providing us with HAP1 and HAP1-AVP33A cells, as well as pMX-FLAG-VPS33A plasmid, Dr. Susan Weiss, University of Pennsylvania, Philadelphia PA, USA, for providing us with the pMH34 derived transcription vector that contains the spike gene of MHV-4, and Dr. Tom Gallagher, Department for Microbiology and Immunobiology, Stritch School of Medicine, Loyala University, Chicago IL, USA for providing us with N-EACAM-Fc antibody. We also would like to thank Prof. Dr. Ari Helenius and the Light Microscopy and Screening Center, Institute of Biochemistry, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, for providing us with the possibility to carry out light microscopy experiments in their facilities and providing us with scientific input.

Author Contributions

Conceived and designed the experiments: CB MHV BLH LP PJMR BJB CAMdH. Performed the experiments: CB MHV BLH. Analyzed the data: CB PJMR. Contributed reagents/materials/analysis tools: OW SIvK LP BLH. Wrote the paper: CB PJMR BJB CAMdH. Provided scientific input: BLH. In charge of the project: CAMdH. Performed the experiments: CB MHV BLH. Analyzed the data: CB PJMR. Contributed reagents/materials/analysis tools: OW SIvK LP BLH. Wrote the paper: CB PJMR BJB CAMdH. Provided scientific input: BLH.

References


